Diabetes treated by Homeopathy Medicine – SBL Clinical report

This is a clinical trial report commissioned and published by SBL to validate the effectiveness of Diaboherb, a homeopathy medicine for treatment of Diabetes. It was conducted by Dr. Harisha.S, Kiran Vuppala of IC Bio Clinical Research Pvt. Ltd Bengaluru in coordination with Dr. Rajanna Muniswamappa,  Bangalore Diabetic Centre and Dr. Beena Thomas (SBL Pvt Ltd).

Clinical Trial of Poly Herbal Product in the Treatment of Type 2 Diabetes Mellitus

Abstract

Background: Diabetes mellitus, often simply referred to as diabetes, is a group of metabolic diseases in which a person has high blood sugar, either because the body does not produce enough insulin, or because cells do not respond to the insulin that is produced. This high blood sugar produces the classical symptoms of polyuria (frequent urination), polydipsia (increased thirst) and polyphagia (increased hunger) and myalgia.

Objectives: The aim of the study is to evaluate the safety and efficacy of Diaboherb in patients with type 2 diabetes mellitus.

Conclusion: “Diaboherb” ( a poly herbal homeopathy medicine form SBL) is found effective in treating the type II diabetes patients with positive outcome on the quality of life like Polyuria (frequent urination), Polydipsia (increased thirst) and Polyphagia (increased hunger)and myalgia.

Keywords: Diaboherb, Fasting blood glucose, Post Prandial blood glucose and HbA1C.

Check out other Top Homeopathic medicine list that are well known in managing diabetes, alleviating its debilitating symptoms and help control associated complications.

Introduction: Type 2 Diabetes

Diabetes Mellitus type 2 (formerly Non Insulin-Dependent Diabetes Mellitus (NIDDM) or adult-onset diabetes) is a metabolic disorder that is characterized by hyperglycemia (high blood sugar). Type 2 Diabetes Mellitus is characterized by insulin resistance, which may be combined with relatively reduced insulin secretion. The defective responsiveness of body tissue to insulin is believed to involve the insulin receptor. However, the specified defects are not known. Diabetes Mellitus cases due to a known defect are classified separately. Type 2 diabetes is the most common type. In the early stage of type 2, the predominant abnormality is reduced insulin sensitivity. At this stage, hyperglycemia can be reversed by a variety of measures and medications that improve insulin sensitivity or reduce sugar production by the liver. The classic symptoms are excess thirst, frequent urination, and constant hunger. Type 2 diabetes makes up about 90% of cases of diabetes, with the other 10 % due primarily to Diabetes Mellitus type 1 and gestational diabetes. Obesity is thought to be the primary cause of type 2 diabetes in people who are genetically predisposed to the disease.

The New break through – Diaboherb  : This is a herbal health supplement which takes care of the complications associated with diabetes, i.e., polyuria, polydipsia, polyphagia, myalgia and complications of diabetes. The effectiveness of Diaboherb will help diabetic patient of (Type 2) by helping reduce complications which may lead to serious consequences. To control sugar levels effectively and to get remote from the complications of the diabetes, diaboherb plays a vital role.

Diaboherb- Clinical report

Clinical Trial

A prospective, randomized, double blind, placebo controlled clinical study to evaluate the efficacy and safety of Diaboherb in patients with Type 2 Diabetes Mellitus

Methodology

A prospective, randomized, double blind, placebo controlled proof of concept study enrolled 150 type II diabetic patients, who met the selection criteria.

Material and Method

Inclusion Criteria

  • Males and Females Patients with Type 2 Diabetes Mellitus with age 30-65 year.
  • Only new cases with inadequate glucose control.
  • Body mass index between 20-35 kg/m2
  • Having fasting blood glucose > 126 mg/dL.
  • Post prandial blood glucose > 200 mg/dL.
  • Having no serious Physical abnormalities other than those generally associated with type 2 Diabetes Mellitus.
  • Patient is willing and able to comply with all trial requirements.
  • Ability to understand the Informed Consent and Willing to Sign on informed consent along with audio video visual in accordance with GCP and local legislation.
  • Patients able to understand and follow the protocol of the trial.
  • Participants who are able to visit the medical institutions throughout the study period.

Exclusion Criteria

  • Patients having Insulin dependent Diabetes Mellitus.
  • Having history of hypersensitivity, liver or kidney damage or gastrointestinal disorders, acute infections, diseases of blood or hematopoietic organs
  • Pregnant or lactating women
  • Patients receiving any concomitant medication, which may have interacted with hypoglycemic action of study drug.
  • Previous participation in a clinical trial in the last 6 months. •

Subjects who are already taking or have taken in the past 2 months any investigational drug.

  • Dehydration by clinical judgment of the investigator.
  • Any contraindication to blood sampling.
  • Severe asthma that is poorly controlled with medication.

 

Ethics Committee Approval

All study related documents Protocol, CRF, Dairy Card, Investigator Brochure, SF-36 and ICF (English and Kannada versions). Written informed consent was obtained from the subject (s) before the start of the trial and after due approval from the Clinical Independent Ethics Committee for Ethics in Research, Bangalore.

END POINTS

Consistent with the primary study objectives, the following endpoints was assessed among study participants

Primary Endpoints

  • Changes in Diabetic Panel Investigations. Secondary End points • Incidence and rate of adverse events • Quality of life questionnaire before and after the treatment ( SF-36 HEALTH SURVEY)

Disposition of Subjects

Total of 150 subjects Drug A : Diaboherb 1(50 Subjects) Drug B:Diaboherb 2 (50 Subjects) Drug C: Placebo (50 Subjects)

Homeopathy Clinical trial 1

Visit details

The patients were screened and enrolled. The enrollment day was considered as the base line data and the patient were asked to visit on: Day 10, Day 20, Day 30, Day 45, Day 60, Day 75 and Day 90.

STATISTICAL ANALYSIS

The data was analyzed with 5% significance level and 80% power for study using SAS. The two sample mean is assessed using paired t – test. The difference between the groups was assessed using One Way ANOVA. Following sets of data emerged that validates the hypothesis that homeopathy medicine effectively treats Diabetes

RESULTS

Efficacy Analysis (For Drug A)

Fasting Blood Sugar (mg/dl)

Table. Fasting Blood Sugar (mg/d1)from screening to end of treatment.

DRUG – A
Screening Fasting Blood Sugar (mg/dl) 144.698
End of Treatment Fasting Blood Sugar(mg/dl 134.557
Reduction in mean 10.14
Percentage reduction in mean(%) 7.008

Homeopathy Clinical Trial Report

Post Prandial Blood Sugar (mg/di)

Table. Post prandial blood sugar(mg/dl) from Screening to end of treatment.

DRUG – A
Screening Postprandial Blood Sugar (mg/dl) 236.557
End of Treatment Postprandial Blood Sugar(mg/dl) 219.5436
Reduction in mean 17.0134
Percentage reduction in mean(%) 7.192

Homeopathy Clinical Trial Report.1

Glycated Hemoglobin (HBA1C) 

Table: Glycated Haemoglobin (HBA1C) (%) from Screening to end of Treatment

DRUG – A
Screening Glycated 4 Hemoglobin (HbAlc)(%) 7.492
End of Treatment Glycated Hemoglobin (HbAlc)(%) 7.372
Reduction in mean 0.12
Percentage reduction in mean(%) 1.602

3.1.1

FBS, PP BS and HbAlc levels (Drug A)

Table. Mean Value of FBS, PPBS and HbA1c Levels

Visit FBS (mg/dL) PPBS (mg/dL) HbAlc (%)

 

Screening 144.698 236.557 7.492

 

End of the treatment(Day -90) 134.557 219.543 7.372

 

4.1

 P Value (For Drug A)        

P Value of FBS, PPBS and HbAlc Levels

P-Value FBS PPBS HbAlc (%)

 

  P Value equals 0.0014

 

P Value is less than 0.0001

 

P Value equals 0.0270

 

Significance

 

Very statistically Significant

 

Extremely Statistically

 

Significant Statistically Significant

 

 Quality of Life (for drug A)

The results collected have shown that the Drug A has improvement in the quality of life by the management of symptoms like fatigue, dry mouth, thirst (Polydipsia), excessive urination (Polyuria), hunger (Polyphagia) and myalgia.

Safety evaluation (for drug A)

No Adverse events were reported for Drug A

Efficacy Analysis (For Drug B)

 Fasting Blood Sugar (mg/di)

Table. Fasting Blood Sugar(mg/dl) from Screening to End of Treatment.

DRUG – B

 

Screening Postprandial Blood Sugar (mg/dl) 144.723
End of Treatment Postprandial Blood Sugar(mg/dl) 134.277
Reduction in mean 10.446 10.446
Percentage reduction in mean (%) 7.218

 

5-1

Post Prandial Blood sugar(mg/dl)

Table:Post prandial blood sugar(mg/dl) from screening to end of treatment.

DRUG – B
 
Screening Post prandial blood sugar(mg/dl) 236.7095
End of Treatment Post prandial blood sugar(mg/dl) 219.0473
Reduction in mean 17.6622
Percentage reduction in mean(%) 7.462

 5

Glycatd Haemoglobin (HBA1C) (%)

Table: Glycatd Haemoglobin (HBA1C) (%) from Screening to end of Treatment

DRUG – A
Screening Glycatd Haemoglobin (HBA1C) (%) 7.422
End of Treatment Glycated Hemoglobin (HbAlc)(%) 7.256
Reduction in mean 0.166
Percentage reduction in mean(%) 2.237

6

FBS, PPBS and HbAlc Levels (Drug B)

Table: Mean Value of FBS, PPB Sand HbA1c Levels

Visit FBS (mg/dL) PPBS (mg/dL) HbAlc (%)

 

Screening 144.723 236.7095 7.422

 

End of the treatment (Day -90) 134.227 219.0473 7.256

 

6.1

P Value (For Drug B)      

P Value of FBS, PPBS and HbAlc Levels

P-Value FBS PPBS HbAlc (%)

 

  P Value equals 0.0010
P Value is less than 0.0001
P Value equals 0.0157
Significance
Very statistically Significant
Extremely Statistically Significant
Statistically Significant

Quality of life (for drug B) :

The results collected have shown that the Drug A has improvement in the quality of life by the management of symptoms like fatigue, dry mouth, thirst (Polydipsia), excessive urination (Polyuria), hunger (Poly phagia) and myalgia.

Safety evaluation (for drug B)

No Adverse events were reported for Drug B

Efficacy Analysis (For Drug C)

Fasting Blood Sugar (mg/dl)

Table. Fasting Blood Sugar(mg/dl) from Screening to End of Treatment.

DRUG – C
Screening Postprandial Blood Sugar (mg/dl) 144.7067
End of Treatment Postprandial Blood Sugar(mg/dl) 138.113
Reduction in mean 6.5937
Percentage reduction in mean (%) 4.557

Fasting Blood sugar Levels - Clinical report Homeopathy

Post prandial Blood Sugar (mg/dl)

Table. Post prandial blood sugar(mg/dl) from Screening to end of treatment.

DRUG – C
Screening Postprandial Blood Sugar (mg/dl) 236.44
End of Treatment Postprandial Blood Sugar(mg/dl 226.76
Reduction in mean 9.68
Percentage reduction in mean (%) 4.094

Post Prandial Blood sugar report - Clinical trial Homeopathy

Glycated Haemoglobin (HBA1C) (%)

Table: Glycated Haemoglobin (HBA1C) (%) from Screening to end of Treatment

DRUG – C
Screening Glycated Haemoglobin (HBA1C) (%) 7.49
End of Treatment Glycated Haemoglobin (HBA1C) (%) 7.44
Reduction in mean 0.05
Percentage reduction in mean (%) 0.67

Glycated Haemoglobin HBA1C report

FBS, PPBS and HbAlc levels (Drug C)

Table. Mean Value of FBS, PPB Sand HbA1c Levels

Visit FBS (mg/dL) PPBS (mg/dL) HbAlc (%)
Screening 144.7067 236.44 7.49
End of the treatment(Day -90) 138.113 226.76 7.44

 

Mean value of Fasting Blood sugar, PPBS & HbA1C level

P Value (For Drug C)

P Value of FBS, PPBS and HbAlc Levels

P-Value FBS PPBS HbAlc (%)
  P Value equals 0.0627 P Value is less than 0.0635 P Value equals 0.3406
Significance

 

Significance Not quite statistically Significant Not quite Statistically Significant Not Statistically Significant

 

Quality of life (for drug C)

The results collected have shown that the Drug C has no improvement in the quality of life because there is no improvement in the symptoms like fatigue, dry mouth, thirst (Polydipsia), excessive urination (Polyuria), hunger (Polyphagia) and myalgia.

Safety evaluation (for drug C)

No Adverse events were reported for Drug C

Discussion & Conclusion

The total number of subjects analyzed in the study (Diabetes treated by Homeopathy medicine) is 150, of which 50 subjects were randomly assigned to the Drug A group, 50 subjects were randomly assigned to the Drug B group and 50 subjects to the Drug C group. The subjects were called for screening visit and were given the Informed consent and screening procedures were started. Once the subjects were screen passed, eventually the subjects were randomized into the group A (Diaboherbl), group B (Diaboherb 2) and Group C (Placebo Group). The blind was broken after Day – 90 when as per the protocol the trial ended.

All individuals, who were included in this study, were analyzed in this report.

The data obtained from the three groups was analyzed statistically using paired t-test. The data was compared between the Active Groups(GroupA,Group B) and Placebo Group (Group C)for the parameters including reduction in blood sugar levels (FBS,PPBS,HbAlc). From the data obtained, it was found that the investigational product Diaboherb was showing significant percentage of increase in reduction of Fasting Blood Sugar(FBS),Post Prandial Blood Sugar(PPBS) levels and HbAlc levels with no adverse effects, which was considered as an important parameter in diabetic controlling.

REFERENCES

  • “Diabetes Blue Circle Symbol”. International Diabetes Federation.17 March 2006.
  • “About diabetes”. World Health Organization. Retrieved 4 April 2014.
  • “Diabetes Fact sheet N°312”. WHO. October 2013. Retrieved 25 March 2014.
  • Kitabchi, AE; Umpierrez, GE;Miles, JM;Fisher, JN(Ju12009). “Hyperglycemic crises in adult patients with diabetes.”.Diabetes Care32(7):1335-43.doi:10.2337/dc09-9032.PMC 2699725PMID 19564476.
  • Shoback, edited by David G.Gardner, Dolores(2011).”Chapter17″.Greenspan’s basic & clinical end ocrinology (9th ed.) New York: McGraw – Hill Medical. ISBN 0-07-162243-8.
  • RSSDI text book of Diabetes Mellitus.(Rev.2nd ed.). New Delhi : Jaypee Brothers Medical Publishers.2012. p. 235.ISBN 9789350254899.
  • “The top lOcauses of death Fact sheet N°310”. World Health Organization.Oct 2013.
  • Rippe, edited by Richard S.Irwin, James M.(2010). Manual of intensive care medicine(5thed.) Philadelphia : Wolters Kluwer Health/LippincottWilliams&Wilkins.p.549.1SBN 9780781799928.
  • Picot,J;Jones,J;Colquitt,k;Gospodarevskaya,E;Loveman,E;Baxter,L;Clegg,AJ(September2009).”The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity : asystematic review and economic evaluation”. Health technology assessment (Winchester, England) 13(41):1-190,215-357, iii—iv.doi:10.3310/hta13410.PMID19726018.
  • Cash, Jill (2014). Family Practice Guidelines (3rded.)Springer.p.396. ISBN 9780826168757.
  • Williams text book of endocrinology(12th ed.)Philadelphia:Elsevier/Saunders.pp.1371-1435. ISBN 978-1-4377-0324-5.
  • Shi,Yuankai;Hu,FrankB. The global implications of diabetes and cancer”. The Lancet 383(9933) : 1947-8. doi:10.1016 /SO140-6736 (14) 60886-2. PMID 24910221.
  • VosT, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V,etal. (Dec15,2012). “Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010 : asystematic analysis for the Global Burden of Disease Study 2010.” Lancet 380 (9859) : 2163-96.doi : 10.1016/S0140-6736(12)61729-2.PMID23245607.
  • IDF DIABETES ATLAS(6thed.),InternationalDiabetesFederation. 2013.p.7.ISBN 2930229853.
  • “International Diabetes Federation : DiabetesAtlas”. Retrieved 4 April2014

• World Medical Association, 13, ch. duLevant, CIB-Batiment A, 01210 Ferney-Voltaire, France;

Warts treated with Homeopathy – Clinical study

Warts treated with homeopathy is a clinical case study that appeared in Schwabe single remedy times (Vol 1, Issue 1) where homeopaths share their experience. Schwabe is a front runner in bringing new information in the field of homeopathy as knowledge exchange tool for homeopathic professionals for effective practice.

About the homeopathic doctor

Doctor’s Name: Dr. Deepak H. Halari
Qualification: M.D. (Nom)
Brief Doctor’s profile: Consulting Homoeopath Address: Reliable Homoeopathic Pharmacy
2, GopalNiwas, R.R.T. Road, Opp. Chetna Hospital, Mulund(W), Mumbai — 400080
Contact No.: 022-25921546, 8454090004, 9167151546 E-mail: dhalari@gmail.com

Patient case history

Mr. A. aged 49 years, residing at Mulund first visited on 13/05/2013

Chief complaint :

  1. Multiple warts over forehead and in scalp since 15 years.
  2. Now they are spreading on face and other body parts since 1 month.
  3. Chronic constipation — no desire for motion unless purgatives taken.
  4. High BP due to hectic job at five star kitchen equipment businesses.
  5. Sleeps very less, only 2 to 3 hours per day never satisfied and in morning he is not fresh; sometimes feels drowsy and unable to concentrate on business.

 

Origin, Duration and Progress – O.D.P.

The patient mainly from Calcutta had shifted to Mumbai 16 years ago. He was very healthy and had no complaint what so ever. But suddenly he had small warts over scalp which were non tender and fungoid type. Initially he neglected but after a period of 3 to 6 months, one more appeared so he met a skin specialist who had advised him cauterization. But he was much afraid to do that so he neglected that disease for nearly 8 years. Afterwards one by one small multiple warts appeared over scalp, but due to that fear of cauterization he did not met any doctor. A friend suggested homeopathy, which he had tried once with the consultation of a homeopath, but warts did not disappear, rather they continued spreading.

After a span of 7 years, a new wart came over forehead since 3 months which was quiet big in size and for the last one month it started spreading to chest and axilla region. Now this made him worry much. He said “as I am working in a five star hotel my business will get affected. Now I must cure this permanently, Doctor please kill this disease forever. Since coming to Mumbai, may be due to change of water, I am constipated and must take purgative for motion, please help me for this too. I also have high blood pressure and since 6 years, I have been taking allopathic medicine for blood pressure but it has never been controlled well. Please look into that as well. Sleep is very less, which is only for 2 to 3 hours. Due to that that I feel sleepy and drowsy throughout the day. Sometimes I was found sleeping in important business meeting which is very embarrassing.”

 

Analysis of case:

If we see the main PQRS symptom is — Indifference, mainly to disease. And when disease is getting more pronounced then he became more fearful and started praying to doctor, he was not ready for cauterization which is the therapy in allopathy, due to fear of hurt by it.

Evaluation of case:

Following rubrics were taken for evaluation of case.

  1. MIND — INDIFFERENCE SUFFERING TO
  2. MIND — INDIFFERENCE COMPLAIN DOES NOT
  3. MIND— DELUSION ABOUT TO RECEIVE INJURY, IS
  4. MIND — ESCAPE ATTEMPT TO
  5. MIND — CAUTIOUS
  6. MIND—ALERT
  7. MIND — DELUSION WELL HE IS
  8. MIND — PRAYING
  9. MIND — AILMENTS FROM EMBARRASSMENT 10.MIND — DELIRIUM BLAMES HIMSELF FOR HIS FOLLY.

 

13-05-2013 – On evaluation

Opium 10M, 3 DOSE at 10 minute interval, followed by sac lac for 20 days.

 

30-05-2013 – No change

SL for 20 days

 

14-06-2013 – the big wart over forhead has fallen & gave him confidence so he wants more stronger dose, but given sac lac for 20 days

14-07-2013 – all most all the warts from scalp and other parts over chest, axilla fallen

sac lac for 20 days

 

11-08-2013– constipation settled and sleep also increased from 2 to 3 hours to 8 hours sound sleep andblood pressure also came under control. Of course allopathy is going on.

15-09-2013 – he told ” Doctor, I am fully cured, feeling as if I am in Calcutta” and gave me invitation for dinner and cocktail party at hotel Leela along with my family.

Image : Investigation window for remedies

Warts treatment in homeopathy - clinical investigation window

Homeopathy medicines for warts – check out our article here for more details

Diarrhea treatment: Clinical trial of homeopathic cure for acute childhood diarrhea

Authors: Jennifer Jacobs, M.D., M.P.H. Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, Washington and  L. Margarita Jimenez, M.D., M.P.H. Department of Public Health, Health Sciences Center, University of Guadalajara and others

Objective: To investigate whether the finding in a previous study that homeopathic medicines decrease the duration of acute diarrhea in children could be replicated in a different study population.

Design: Randomized, double-blind, placebo-controlled trial of diarrhea treatment

Setting: Private, charitable health clinic in Kathmandu, Nepal.

Subjects: A consecutive sample of 126 children, 6 months to 5 years of age, who presented during April through June, 1994, with more than three unformed stools in the previous 24 hours.

Intervention: Children received either an individualized homeopathic medicine or placebo, to be taken one dose after each unformed stool for 5 days. Parents recorded daily stools on diary cards, and health workers made home visits daily to monitor children on diarrhea treatment

Outcome measures: Predefined measures were based on the previous study: (1) duration of diarrhea, defined as the time until there were fewer than three unformed stools per day, for two consecutive days, and (2) Average number of stools per day for each group.

Results: Of the 126 children initially enrolled, 116 completed treatment. The mean number of stools per day over the entire 5-day treatment period was 3.2 for the treatment group and 4.5 for the placebo group (P = 0.023). A Kaplan-Meier survival analysis of the duration of diarrhea, which included data from all patient visits, showed an 18.4% greater probability that a child would be free of diarrhea by day 5 under homeopathic treatment (P = 0.036).

Conclusions: These results are consistent with the finding from the previous study that individualized homeopathic treatment decreases the duration of diarrhea and number of stools in children with acute childhood diarrhea. The results prove that homeopathy is effective in diarrhea treatment in children and results replicated across different population groups.

 

Source: AYUSH RESEARCH PORTAL, Ministry of AYUSH, Government of India

 

FULL PAPER PDF AVAILABLE – CLICK HERE

 

Check here for online Homeopathic specialty medicines for diarrhea treatment

Homeopathy research-Animal Study-effects of Chamomilla, Damiana & Muira puama

We present you Homeopathic study reports of contemporary importance and in this article we cover the research done on animals with respect to Chamomilla, Damiana & Muira puama.

Chamomilla - Homeopathic pharmacological activity

  1. Effect of Homeopathic Chamomilla on Central Nervous System of experimental Animals

This study was aimed to eventuate the effects of 3x, 30CH and 0/3 potencies of Chamomilla on Central Nervous System in experimental animal by using the screening methodologies known in modern psychoneuro­-pharmacology like Acto-photometer, Roto-rod apparatus, Eddy’s hot plate and maximal — electro shock method. The results were statistically processed by analysis of variance test (ANOVA) to compare the effects on treatment group and Dunnet’s t test were used to determine the effect of each treatment against control group. The results showed that Chamomilla 0/3 significantly reduced locomotor activity (movements), exhibit muscle relaxant activity than Chomomillo 3x and 30 CH

(Chamomilla 0/3 is manufactured by Schwabe India in the group of LM potency)

Reference: A.8 Rom jyothis: A Study on Effect of Matricaria chamomilla Potencies on Centrol Nervous System of Experimental Animal, Asian Journal  of Homeopathy, Vol.2 No.2(3) May 2008

 

 Damiana - Homeopathic Herb qualities

  1. Stimulating property of Damiana extracts on the sexual behavior of male rats

Sexually potent and sexually sluggish/impotent mole rats were treated orally with different amounts of Tumero diffuse (Damiana) and Proffitt poniculata fluid extracts-singly or in combination – improved the copulatory performance (act of penis going into the vagina) of sexually sluggish/impotent rats. The extracts also increased the percentage of rats achieving ejaculation and significantly reduced mount, intromission and ejaculation latencies, post-ejaculatory interval and intercopulotory interval. Neither extracts affected locomotor activity.

(Schwabe’s Damiaplant contains basically  Damiana. It is also available in mother tincture)

Reference: Arletti, A. Benelli, E. Cavazzuti, G. Scarperto and A. bertolini, Stimulating property of Turnera diffusa  and Pfaffia  paniculata extractson the sexual behavior of male rats, Psycho-pharmacology. Volume 143, Number 1/ march. 1999

 

  Muira Puama - nerve tonic, libido enhancer

  1. Effects of Muira Puama in the chronic mild stress model

Muira puorno, is regarded as o “nerve tonic”. Traditional uses include states of lassitude with noticeable lock of desire/motivation, and to manage particularly stressful (physical and/or psychological) circumstances. Suggestive of antidepressant activity, the authors hove established that o specific PO ethanol extract (POEE) significantly decreases immobility in the tail suspension and forced swimming tests. The aim of this study was to verify the effects of POEE in the unpredictable chronic mild stress (UCMS) depression model in mice, given the construct and face valves of the UCMS as on experimental model of depression and the traditional use of this species. Over 6 weeks BALB/c mice were subjected to the UCMS protocol.

The effects of POEE and imipramine were evaluated in relation to coat state, splash-test grooming, and corticosterone levels. The coot state degradation, decreased grooming and increased serum corticosterone induced by UCMS were prevented by POEE and imipramine treatments. Authors have concluded that in addition to supporting traditional claims and previously reported antidepressant properties for POEE, this study shows that POEE prevents stress-induced HPA hyperactivity.

(Muira puama is a Brozlian plant. The mother tincture is manufactured from imported herb and marketed by Schwabe India).

Reference:  Piato AL, Detanico BC. Jesus JF, thullier FL. Nunes DS. Eltsobetsky E. Effects of Muira puama in the chronic mild stress model: Further indication at ontideptessont propenies.lthhnopholmacol. 2008, July 23;118(2):300-304